Astrana Health, Inc. (ASTH) Stock Forecast
ASTH analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 11 analysts
- Price target
- $51.67 average of analyst targets
- Upside to target
- +40.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.44
- 52-week range
- $18.16 – $49.81
ASTH analyst ratings
11 analystsNumber of analysts at each rating.
ASTH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ASTH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.88 | $0.83 | $0.91 | $0.68 | +29.9% | 3 |
| Current fiscal year (2026) | $3.07 | $2.94 | $3.14 | $2.12 | +44.5% | 3 |
| Next fiscal year (2027) | $3.64 | $3.41 | $3.83 | $3.07 | +18.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ASTH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.02B | $1.01B | $1.03B | +6.7% | 10 |
| Current fiscal year (2026) | $3.98B | $3.96B | $4.03B | +25.1% | 10 |
| Next fiscal year (2027) | $4.38B | $4.24B | $4.59B | +10.1% | 10 |
ASTH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ASTH revenue: reported and forecast
ASTH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.79 | $0.79 | $0.86 | $0.86 | $0.88 | +11.0% | 2 up · 0 down |
| Current fiscal year (2026) | $2.92 | $2.92 | $3.04 | $3.04 | $3.07 | +5.0% | 2 up · 0 down |
| Next fiscal year (2027) | $3.41 | $3.42 | $3.54 | $3.54 | $3.64 | +6.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ASTH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ASTH beat in 10 of 12.
What analysts expect from ASTH
11 analysts cover Astrana Health; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $51.67, 40.4% above the latest close of $36.81. Analysts expect earnings of $3.07 per share for 2026, +44.5% from a year earlier. For 2027 the average estimate is $3.64 per share on revenue of $4.4 billion. Astrana Health beat the EPS estimate in 10 of the last 12 quarters.
Related: ASTH income statement, ASTH key metrics, ASTH chart. See the ASTH stock overview for the latest quote and news.
ASTH forecast FAQ
What is Astrana Health's price target?
The average analyst price target for Astrana Health is $51.67, 40.4% above the latest close of $36.81.
Is Astrana Health a buy, hold or sell?
Of 11 analysts covering Astrana Health, 8 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Astrana Health's EPS forecast?
Analysts forecast $3.07 per share for 2026 (range $2.94 to $3.14); for 2027 the estimate is $3.64.
What is Astrana Health's revenue forecast?
The average revenue estimate for 2026 is $4.0 billion, growth of 25.1%; for 2027 it is $4.4 billion.
When does Astrana Health report earnings?
Astrana Health is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $0.44.
Does Astrana Health usually beat earnings estimates?
Astrana Health reported EPS at or above the analyst estimate in 10 of the last 12 quarters.